Background: Biological therapy is indicated in the treatment of RA (Rheumatoid Arthritis) after failure of disease-modifying anti-rheumatic drugs (DMARDS) by the ACR/EULAR recommendations. The objective of the study is to describe the characteristics of Saudi patients at the initiation of biological therapy and to evaluate clinical effectiveness of this therapy measured by the disease activity score DAS 28. Methods: This was a retrospective cohort study of RA (rheumatoid arthritis) patients in King Fahad Hospital in Jeddah, Saudi Arabia from January 2005-July 2011. Data were collected from the medical records of all RA patients on biological therapy including: demographics, disease characteristics, comorbid illnesses and DAS 28 score over a period of 1 year. Results: 139 patients were studied (mean age 46 ± 13 years), of which 118 (84%) were females; mean duration of affliction with RA was 7.2 years ranging 1 -45 years. Rheumatoid factor (RF) was positive in 88 patients (63.3%) and one or more comorbidities were present in 102 patients (73.3%). First choice of biological drug was ADA (Adalimumab) 44 patients (31.7%) and RTX (Rituximab) was the 2 nd frequently prescribed biological drug. Mean DAS 28 activity at baseline was in ADA 41 patients (6.10 ± 1.62), ETA (Etarnercept) 29 patients (6.64 ± 1.42) and RTX 50 patients (6.7 ± 1.32). Moderate to good EULAR response was obtained in 74%, 85.7% and 53.3% at 6 months in ADA, ETA and RTX patients respectively. Moderate to good EULAR response was obtained in 61.8%, 86.6% and 72% in ADA, ETA AND RTX patients respectively at 1 year of treatment. Therapeutic effectiveness was comparable with the response rates in published observational trials. Conclusion: Our data demonstrate daily clinical practice in management of RA. The pattern of prescription is in agreement with the ACR/EULAR recommendations for initiation of biologicals in the treatment of RA.
Introduction
The introduction of biological therapies has dramatically changed the armament of treatment of Rheumatoid arthritis (RA). Randomized placebo-controlled trials (RCT) on Infliximab (INF) [1] - [3] , Etarnercept (ETA) [4] - [7] , Adalimumab (ADA) [8] - [10] , and rituximab (RTX) [11] - [13] have all shown to be very effective at improving the symptoms and signs of RA and at preventing structural joint damage and loss of function in diseasemodifying anti-rheumatic drug (DMARD)-resistant disease. Use of biological DMARDs has increased over the past 15 years and ACR/EULAR recommendations to advocate early use of biological agents following an insufficient response to initial non-biological DMARD therapy [14] [15] . The primary goal of RA treatment is remission or low disease activity [16] - [18] ; in other words, the concept of "Treat to target" has been adopted to maximize long-term health-related quality of life through control of symptoms, prevention of structural damage, normalization of function, and social participation [19] . Therapies targeted to minimize disease activity lead to achievement of treatment goals.
The researchers conduct this study to examine the functionality of the available biological DMARDs treatments in Saudi Arabia, which are not far from implementing these therapies in pace with the international recommendations. Initially INF was first introduced in the national health formulary of Saudi Arabia in 2005 for the treatment of RA patients. Subsequently ADA was approved in 2008 by the Saudi Health Authorities with expanding the use of anti-TNF for other inflammatory disorders including ankylosing spondylitis and psoriatic arthritis. RTX was already presented in the national formulary for oncology patients and was later approved for the treatment of RA in 2008. ETA was registered in 2009. Biological DMARDs therapy is prescribed on the basis of current international and national recommendations. However, patients treated in daily clinical practice differ from those in clinical trials with strict inclusion criteria. Once the biological therapy is registered by the Saudi health authorities, there is no limitation in prescribing the medication by the rheumatologist to any Saudi citizen if needed in his management.
The objective of the study is to describe characteristics of Saudi RA patients at the initiation of biological DMARDs therapy and to evaluate clinical effectiveness of this therapy measured by DAS 28, in our rheumatology unit in King Fahad Hospital, Jeddah western Saudi Arabia which is a referral center from Jeddah as well as the surrounding small districts.
Methods
The study was approved by the local institutional review and ethical board committee and was conducted in a single tertiary center by collecting all cases on biological DMARDs therapy prescribed for RA through the hospital main pharmacy in King Fahd Hospital, Jeddah from 2005 till July 2011. It is a retrospective case series, in which the exclusion criteria are limited to the contraindications stated in the Summary of the Product characteristics (SPC) of each drug. Information was retrieved from the medical records of the patients by using a data sheet for RA patients on biological therapy regarding patient demographics and characteristics, including indications, disease duration, comorbidities, clinical, radiological and laboratory features. These are: (disease duration, extra-articular manifestations, tender and swollen joint counts, visual analog scale, erythrocyte sedimentation rate, rheumatoid factor (RF), anti-citrullinated peptide antibodies ACPA and evidence of erosions on hand XRay films). Previous DMARDS was checked, as well the number of disease modifying drugs used before start of biologicals. History of tuberculosis (TB) or previous exposure to contacts or family histories are documented, screening for latent TB are obtained and if positive, it is asked wither prophylactic treatment with isoniazide (INH) was given. Efficacy was assessed using DAS 28 [20] for RA. Baseline 0, 6, 12 months evaluation were recorded. Outcomes at 6 and 12 months were categorized according to the DAS scores. Based on the European League against Rheumatism (EULAR) Improvement Criteria [21] , individual patients are classified into three groups: no response, moderate response and good response, based on their 6 month DAS 28 and absolute change in the DAS 28 from baseline. A good responder must demonstrate an improvement of at least 1.2 units and achieve an absolute score of <3.2. A non-responder should demonstrate an improvement of <0.6 or have a final DAS 28 > 5.1. Moderate response falls in between. Patients achieved remission according to the EULAR criteria when the DAS 28 < 2.6.
Planned Statistical Analysis
Data was analyzed using the statistical package of social science (SPSS-16) database program.
Descriptive statistics was done including number of observations, mean, minimum and maximum for continuous variables: count and percentages for categorical variables. Differences between the categorical variables were tested using the Pearson's Chi2 test and Yates correction was used when indicated. Differences between the continuous variables were tested using the one-way Annova (F test). A p-value < 0.05 was considered significant.
Results
The baseline characteristics at the start of the biological therapy are presented in Table 1 . One hundred and thirty nine patients were studied, (mean age 46 ± 13 years), ranging from 19 -97 years of which 118 (84%) were females; mean duration of the RA was 7.2 ± 6.4 years. Those that presented with disease duration > 1 year were 121 (75.6%) of RA patients. RF was positive in 88 patients (63.3%) and ACPA was positive in 110 patients (78.4%) of the patients. Lung fibrosis was present in 8 patients (11.12%). One or more comorbidities were present in 102 patients (73.3%). Rheumatoid nodules were present before the start of therapy with ADA 6 patients, ETA 3 patients, INF 3 patients, and RTX 7 patients. All had complete resolution of the nodules except for 1 patient on INF.
First choice of biological drug was ADA 44 patients (31.7%), ETA 32 patients (23%), IFA 22 patients (15.8%), and RTX in 31 patients (22%). RTX was the most frequently prescribed 2nd biological drug. Present biological treatment at the time of analysis was with ADA 45 patients (32.4%), ETA 35 patients (25.2%), INF 6 patients (4.3%), and RTX 53 patients (38.1%).
Mean DAS 28 activity at baseline was in ADA is 41 patients (6.10 ± 1.10), ETA 29 patients (6.60 ± 1.30), and RTX 50 patients (6.7 ± 1.32) as shown in Table 2 . INF was excluded from final analysis due to the very small number of patients as well as missing data at follow-up. Mean DAS 28 activity at 6 months in patients on ADA 27 patients (3.69 ± 1.52), ETA 21 patients (3.94 ± 1.35) and RTX 35 patients (4.63 ± 2.01); Mean DAS 28 activity at 12 months on ADA 22 patients (4.36 ± 1.72), ETA 15 patients (3.69 ± 1.57), and in RTX 25 patients (4.03 ± 1.69) with significant p<0.05 was observed at 6 and 12 months in all the 3 drugs. Table 3 indicates that remission was obtained in 8 patients (29.6%) and 4 (19.6%) on ADA at 6 and 12 months respectively; 3 patients (14.3%) and 5 patients (33.3%) obtained remission on ETA at 6 and 12 months respectively. Patents on RTX achieved remission in 5 patients (14.3%) and 4 patients (16%) at 6 and 12 months respectively. Moderate to good EULAR response, as shown in Table 4 , was obtained in (74%), (85.7%), and (53.3%), at 6 months in Table 2 . Mean disease activity of RA patients on Adalimumab, Etarnercept and Rituximab at 0, 6 and 12 months.
DAS 28
Adalimumab n (%) P-VALUE Etarnercept n (%) P-VALUE Rituximab n (%) P-VALUE ADA, ETA and RTX patients respectively. Moderate to good EULAR response was obtained in 61.8%, 86.6% and 72% in ADA, ETA, and RTX patients respectively at 1year of treatment. Therapeutic effectiveness was comparable with the response rates in published observational trials.
Discussion
Our study describes the practice of a single rheumatology center King Fahad Hospital in prescribing biological DMARDs therapy in the management of RA. To our knowledge, this is the first single center cohort addressing initiation and effectiveness of biologically treated RA patients in Saudi Arabia. Real life observational cohort studies add imperative knowledge to data derived from RCTs with their strict inclusions criteria. The demographic characteristics of the patients were comparable across the cohorts in the other observational studies as in GLADER, DREAM and DANBIO registries [22] - [24] . Our patients had long standing disease with a mean 7.2 ranging from 1 -45 years with failure of two or more DMARDs and the mean DAS 28 score 6.82 (± 1.38) in implementation of the EULAR/ACR guidelines for the initiation of biological therapy. Only 12% of our patients had disease duration of less than one year reflecting the importance of early referral and early disease control. The first choice of biological therapy was ADA and the second choice biological therapy after the failure of the first was RTX, which is consistent with the ACR/EULAR recommendations [14] [15] [23] . The choice of biological agent was strongly associated with the preferences of the individual doctors, the year of treatment initiation, and availability of the drug in the hospital. Therefore, INF was the first in 2005, ADA and RTX in 2008, and ETA was in 2009.
In our cohort of RA patients the DAS 28 at 6 months and 12 months for patients on ADA was 3.7 ± 1.5 and 4.4 ± 1.72 respectively with a significant p-value < 0.001. Moderate to good EULAR responses. DAS 28 ≤ 3.2 was obtained in 75% and 62% at 6 months and 12 months [10] . This is in contrast to the DANBIO registry which showed a slight increase in good to moderate EULAR response in 85% and 86% at 6 and 12 months [24] . A slight increase of DAS 28 activity was seen at 12 months in our cohort which could be explained with the periods of drug unavailability especially the end of each year when a new drug is introduced in a governmental institute.
The RA patients on ETA, the mean DAS 28 activity at 6 months and 12months was 3.9 ± 1.35 and 3.69 ± 1.57 respectively with a significant p < 0.001. Good and moderate EULAR response was seen in 85% and 86% at 6 months and 12 months as was seen in others studies as in the Hellenic registry [25] , by Kievit et al. [26] and by Zink and his colleagues [27] . Only 44% of the ETA group had comorbid illnesses.
Patients in the RTX had a long duration of disease 8.4 years with one or more comorbidities in 77.6% and use of two or more DMARDS in 80% and failure of previous anti-TNF therapy. It was the most commonly used 2nd choice of biological DMARDs therapy in RA patients. In 22% of all the RA patients on biological DMARDs RTX was used as the first line drug in those patients who refused anti-TNF or because of contraindications such as prior malignancy, presence of connective tissue disease, previous tuberculosis or those patients from remote areas surrounding Jeddah having problems with compliance with subcutaneous therapy. According to the EULAR response criteria, 53.3% of the patients on RTX achieved good to moderate response at 6 months in agreement with results from the observational study by Moetaza et al. [28] However the response in a randomized REFLEX trial [12] was slightly higher (65%) due to strict inclusion criteria used in clinical trials omitting non trivial comorbidities. IFX was the first drug available in our center since 2005 as the first choice of biological DMARDs but once the subcutaneous biological therapy were available it was reserved for other CTD due to limited beds in the day care unit. INF was excluded from the final analysis due to the small number and due to the large amount of missing data. Our study has some limitations given the retrospective nature of the study. Though IFX was started early as 2005, composite measures were not used initially for the assessment for response to therapy.
Conclusion
The data presented in this study present "real world patients" and realistic clinical practice. The results from this retrospective study indicate our practice is in consistence of the ACR/EULAR guidelines in the initiation of biological therapy. The actual response observed in our cohort was slightly lower than the results obtained in randomized controlled trials but consistent with published observational cohort studies describing daily practice. With the widening of the paradigm of management of RA, national registries are of great importance with a major advantage over industry-driven observational post-marketing studies for long-term evaluation of safety and effectiveness of the new generation of biological therapy.
